title: [Pertuzumab (PERJETA(®) intravenous infusion 420 mg/14 mL): pharmacological properties and clinical development overview].
authors: Hiroshi
authors: H
authors: Myobudani
authors: Naomi
authors: N
authors: Ushiyama
authors: Ryota
authors: R
authors: Ichinose
authors: Tsuyoshi
authors: T
authors: Takasuka
mesh_terms: D000818:Animals; D061067:Antibodies, Monoclonal, Humanized / Q000008:administration & dosage* / Q000009:adverse effects / Q000494:pharmacology; D000970:Antineoplastic Agents / Q000008:administration & dosage* / Q000009:adverse effects / Q000494:pharmacology; D001943:Breast Neoplasms / Q000188:drug therapy* / Q000235:genetics / Q000473:pathology; D002471:Cell Transformation, Neoplastic / Q000187:drug effects; D055808:Drug Discovery; D004357:Drug Synergism; D004359:Drug Therapy, Combination; D006801:Humans; D007262:Infusions, Intravenous; D016032:Randomized Controlled Trials as Topic; D018719:Erb-b2 Receptor Tyrosine Kinases; D000068878:Trastuzumab; D014407:Tumor Cells, Cultured
chemical_list: D061067:Antibodies, Monoclonal, Humanized; D000970:Antineoplastic Agents; D018719:Erb-b2 Receptor Tyrosine Kinases; D000068878:Trastuzumab; C508053:ERBB2 protein, human; C485206:pertuzumab